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Myocardial ischemia and infarction are associated with sub-
stantially increased morbidity and mortality among patients with
diabetes mellitus. Although many factors contribute to the in-
creased morbidity and mortality, in patients with non–insulin-
dependent (type II) diabetes mellitus, one contributor may be the
use of sulfonylurea drugs, the most widely used oral hypoglycemic
agents. Such a possibility, which first arose over a 25 years ago
when it was observed that patients taking sulfonylurea drugs had
increased cardiovascular mortality, has recently resurfaced after
the discovery that sulfonylureas act by inhibiting adenosine
triphosphate (ATP)-sensitive potassium channels. In the pan-
creas, inhibition of ATP-sensitive potassium channels induces
release of insulin; but in the heart, inhibition of these channels
prevents ischemic preconditioning, an endogenous cardioprotec-
tive mechanism that protects the heart from lethal injury. This
review outlines the current understanding of the molecular and
cellular pharmacodynamics of sulfonylurea drugs and discusses
the potential clinical consequences of inhibition of ATP-sensitive
potassium channels in the heart of diabetic patients with cardiac
disease in whom the use of sulfonylureas may be harmful.
(J Am Coll Cardiol 1998;31:950–6)
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Diabetes mellitus is associated with significant cardiac morbid-
ity and mortality, with a more than threefold increased risk of
coronary ischemic events and congestive heart failure, even
after adjustment for multiple risk factors (1,2). Patients with
diabetes also have an increased incidence of late complications
and increased mortality after acute myocardial infarction and
coronary angioplasty, despite similar rates of infarct-related
vessel patency or initial angiographic results indistinguishable
from patients without diabetes (3–8). These data have led to
the realization that patients with diabetes represent a unique
group, requiring alternative strategies for management of
ischemic cardiac disease.
Although efforts to reduce cardiovascular mortality in pa-
tients with diabetes should focus on improving glycemic con-
trol (9), other factors unique to the diabetic patient have been
considered. In patients with non–insulin-dependent (type II)
diabetes mellitus, one factor that might contribute to increased
morbidity and mortality is the use of sulfonylurea drugs. Such
a notion was first raised more than two decades ago on the
basis of epidemiologic data, although the methodology of the
study was criticized (10). In light of the discovery of the
mechanism of action of sulfonylurea drugs, which act through
inhibition of a metabolism-sensitive channel—the adenosine
triphosphate (ATP)-sensitive potassium (KATP) channel,
present in both pancreatic beta-cells (11) and cardiomyocytes
(12), the controversy as to whether use of sulfonylurea drugs
increases the susceptibility of the diabetic myocardium to
ischemic insult deserves reconsideration (13).
The purpose of this overview, therefore, is to outline the
current understanding of the cellular effects of sulfonylurea
drugs within the ischemic myocardium and to discuss the
potential relevance of recent findings at the cellular level to the
clinical use of sulfonylurea drugs in patients with diabetes
mellitus and cardiac disease.
Historical Aspects
The hypoglycemic property of the sulfonylurea drugs was
first described over a half a century ago (14). Soon thereafter,
sulfonylureas were introduced into clinical practice, such that
by the mid-1960s their use in the treatment of patients with
non–insulin-dependent diabetes mellitus was widely estab-
lished. In the early 1970s, however, the University Group
Diabetes Program (UGDP), a 12-center prospective trial de-
signed to compare the efficacy of oral hypoglycemic treatment
with insulin and diet alone, reported a substantially increased
cardiovascular mortality among patients taking the sulfonyl-
urea drug tolbutamide (10). After report of these findings, and
despite much controversy regarding the methodology of the
study (15), use of sulfonylurea drugs fell substantially. How-
ever, by the late 1970s, perhaps because the UGDP findings
could not be confirmed in other, albeit smaller studies (16,17),
sulfonylurea drug use increased once more. Today, sulfonyl-
urea drugs, such as glyburide (glibenclamide), chlorpropr-
amide and glipizide, are the mainstay of therapy in patients
with non–insulin-dependent diabetes mellitus (18,19). Al-
though newer formulations continue to be approved, their
principal target of action remains the KATP channel.
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Sulfonylurea Drugs Inhibit
Membrane-Associated Potassium Channels
in Pancreas and Heart
Pancreas. The hypoglycemic effect of all sulfonylurea
drugs occurs through inhibition of KATP channels in beta-cells
of the pancreas (11,20,21). These channels are so called
because flux of K1 through the channel pore is regulated by
intracellular ATP (22). A surge in blood glucose leads to
increased production of the high energy phosphate ATP, which
inhibits KATP channel opening. With channel closure, an
excess of positively charged K1 remains on the inner side of
the plasma membrane, leading to depolarization of the beta-
cell plasma membrane. Membrane depolarization induces
opening of voltage-dependent Ca21 channels followed by
Ca21-dependent release of insulin through exocytosis (23–27)
(Fig. 1). It is also through this mechanism that sulfonylurea
drugs promote release of insulin. Sulfonylurea drugs bind, with
high affinity, to a subunit of the KATP channel, known as the
sulfonylurea receptor (SUR) (28). Occupancy of this receptor
by a sulfonylurea drug inhibits flux of K1 through the channel
pore, depolarizing the plasmalemma and inducing release of
insulin (Fig. 1).
Heart. KATP channels are also abundantly distributed
within the sarcolemmal membrane of cardiac cells (22). In an
individual cardiomyocyte, there are estimated to be ;5,000
channels/cell (12,22). Opening of only a fraction of KATP
channels can have a profound effect on cardiac excitability
(12). Sulfonylurea drugs also inhibit cardiac KATP channels
(29,30) and have been used extensively to better understand
the function of these channels in the heart, although the
efficacy with which sulfonylureas inhibit channel opening ap-
pears to be determined by the metabolic state of the cardiac
cell (30–33).
Under physiologic conditions, cardiac KATP channels re-
main closed because of their high sensitivity toward intracel-
lular ATP, present at high levels within cardiomyocytes (12).
During myocardial ischemia, ATP can no longer prevent the
opening of KATP channels. Although a discrepancy exists
between the millimolar levels of ATP present within a cardiac
cell and the micromolar sensitivity of the channel toward
ATP-induced channel inhibition (12), a number of intracellu-
lar factors act to reduce the sensitivity of the channel toward
ATP. These include nucleotide diphosphates, acidosis, lactate
production, disruption of the cytoskeleton, phosphotransfer
reactions and entry of the channel into ligand-insensitive
conformational states (12,34–39). Although the precise role of
KATP channels in the heart is not fully understood (12),
opening of cardiac KATP channels initiates ischemic precondi-
tioning and alters cellular excitability during ischemia.
Sulfonylureas Impair
Ischemic Preconditioning
Ischemic preconditioning and role of KATP channels. Isch-
emic preconditioning is now recognized as a powerful, endog-
enous mechanism by which the heart can protect itself from
lethal ischemic insult (13). The phenomenon was first de-
scribed over a decade ago, when it was found that exposure of
the myocardium to brief episodes of mild myocardial ischemia
“preconditioned” the myocardium, markedly reducing the
impact of subsequent prolonged ischemia (40). In the absence
of ischemic preconditioning, complete occlusion of a major
coronary artery leads to myocardial infarction (Fig. 2, top).
However, the preconditioned myocardium, by virtue of its
increased resistance to ischemic insult, is less vulnerable, which
translates to a reduction in infarct size (Fig. 2, middle).
Although the cellular mechanisms by which ischemic pre-
conditioning protects the myocardium during ischemic insults
are only partially understood, ischemic preconditioning pro-
tects the myocardium independently of an increase in coronary
collateral flow (13,40–42). Evidence for the role of the KATP
channel in ischemic preconditioning comes from the finding
that the beneficial effect of ischemic preconditioning can be
mimicked, at least in certain species, by endogenous openers of
Abbreviations and Acronyms
ATP 5 adenosine triphosphate
ECG 5 electrocardiogram
KATP 5 adenosine triphosphate-sensitive potassium channel
Kir 5 inwardly rectifying potassium channel subunit
SUR 5 sulfonylurea receptor
UGDP 5 University Group Diabetes Program
Figure 1. KATP channels. Targets of action of sulfonylurea drugs in the
pancreatic beta-cell. Sulfonylurea drugs induce release of insulin by
inhibiting KATP channels present in the cell membrane of pancreatic
beta-cells. In the presence of high blood glucose levels, glucose is
transported into the cytosol of the pancreatic beta-cell, where it
promotes synthesis of intracellular ATP, which blocks KATP channels
and prevents K1 efflux through the channel pore, leading to membrane
depolarization and opening of voltage-sensitive Ca21 channels, which
allows influx of calcium and, in turn, release of insulin through
exocytosis.
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these channels, such as adenosine, which increases during
ischemia, as well as by synthetic openers of these channels,
known as potassium channel openers, which are useful clinically
in the treatment of angina pectoris (41,43–50). In contrast, loss
of ischemic preconditioning can be induced by blockers of
KATP channels, such as the sulfonylurea drugs (13,51) (Fig. 2,
bottom). Thus, opening of cardiac KATP channels is believed to
be crucial for ischemic preconditioning to occur (13). Sulfo-
nylurea drugs, which may have effects beyond inhibition of
KATP channels (52–56), target cardiac KATP channels and
therefore may be harmful to the ischemic myocardium by
blunting the KATP channel-dependent component of the isch-
emic preconditioning response (13).
Clinical evidence for sulfonylurea-induced impairment of
ischemic preconditioning. Ischemic preconditioning has been
demonstrated repeatedly in the human heart (13,57–60). Us-
ing sequential balloon inflations during coronary angioplasty
or intermittent aortic cross-clamping during coronary artery
bypass graft surgery, it has been possible to demonstrate a
decrease in clinical indicators of ischemia severity, such as
intensity of ischemic pain, extent of ST segment deviation from
baseline and severity of regional wall abnormalities by echo-
cardiography, as well as improved recovery of myocardial
function after cardiac surgery (13,58–60). In other studies, the
presence of angina before myocardial infarction has been
associated with reduced infarct size, preservation of ventricular
function and lower in-hospital mortality (61–63). Ischemic
preconditioning is also believed to be the basis for the “warm-
up” phenomenon, first described by Heberden (64) in the 18th
century, in which patients experience more severe angina pain
during initial exercise that decreases in intensity with subse-
quent exercise (65). This phenomenon has also been observed
in patients undergoing serial exercise testing (66). In contrast,
loss of the preconditioning response has consistently been
observed in the presence of sulfonylurea drugs (13,60,67). Such
findings demonstrate that in humans, ischemic preconditioning
can be induced and has a cardioprotective effect that is
abolished by sulfonylurea drugs.
However, not all studies have found unequivocal evidence
for ischemic preconditioning in the human heart (68–71). One
explanation for this is the presence of numerous confounding
variables in clinical practice. In particular, determination of
infarct size in humans by means of currently available clinical
tools lacks specificity (72), which is necessary to allow precise
demonstration of the cardioprotective effect of ischemic pre-
conditioning. In addition, it is apparent that a narrow window
exists for the development of ischemic preconditioning, lead-
ing to difficulties in the standardization of preconditioning
protocols for the clinical evaluation of the efficacy of this
cardioprotective phenomenon. Such factors could have con-
tributed to the inconsistent results found to date in studies
trying to determine the full potential of ischemic precondition-
ing in clinical practice (67–71).
At the cellular level, it is also becoming increasingly appar-
ent that the interaction between sulfonylurea drugs and cardiac
KATP channels is complex. Recent work investigating the
determinants of KATP channel opening under ischemic condi-
tions and KATP channel inhibition by sulfonylureas has found
that the action of sulfonylureas is not uniform, but is governed
by factors such as nucleotide diphosphates, lactate, and H1, as
well as the channel microenvironment and operative condition
(33,73–75). Thus, inhibition of the KATP channel is not simply
determined by the mere presence of inhibitory ligands
(39,76,77), and the outcome of the action of sulfonylureas on
cardiac cells may vary depending on the cellular metabolic
state (78). These findings further highlight the difficulties faced
in establishing the signaling role of KATP channels in precon-
ditioning and in predicting the consequences of KATP channel
inhibition by sulfonylurea drugs in the human heart.
Sulfonylurea Drugs Also Affect
Cardiac Excitability
The electrophysiologic consequence of cardiac KATP chan-
nel opening may be both proarrhythmic and antiarrhythmic
(79,80). This apparent paradox can, at least in part, be
explained through understanding the role played by KATP
channels in determining the duration of the cardiac action
potential in the ischemic myocardium. In the absence of
myocardial ischemia, cardiac action potential duration is de-
termined by changes, with respect to time, in the vector sum of
Figure 2. Ischemic preconditioning and sulfonylureas. Top, Prolonged
occlusion of an epicardial coronary artery leads to myocardial infarc-
tion. Middle, Repeated and brief occlusion of the same vessel condi-
tion the myocardium such that subsequent, prolonged occlusion leads
to an infarct of diminished size. This phenomenon is called ischemic
preconditioning. Bottom, Sulfonylurea drugs abolish ischemic precon-
ditioning, resulting in a large infarct size.
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inward and outward currents flowing through sarcolemmal ion
channels. Under this circumstance, ion conductance through
KATP channels does not contribute to the action potential
because the channel is inhibited by high levels of intracellular
ATP. However, with myocardial ischemia, intracellular ATP is
no longer able to inhibit KATP channel opening. Under this
condition, K1 efflux through KATP channels is sufficient to
induce significant shortening of the action potential duration
(79–81), which could have two (opposing) consequences: 1)
Shortening of the action potential duration reduces the influx
of Ca21 into the cell through voltage-gated Ca21 channels
because these channels now open for a shorter period. In turn,
the decrease in intracellular Ca21 accumulation reduces the
likelihood of abnormal arrhythmias caused by “triggered ac-
tivity” arising from Ca21-dependent delayed afterdepolariza-
tions (82–84). 2) Shortening of the action potential duration
alters the refractoriness of the myocardium, which could result
in an increased occurrence of arrhythmias caused by reentrant
mechanisms, such as ventricular fibrillation (85–87). By pre-
venting shortening of the action potential duration through
inhibition of KATP channel opening during ischemia, sulfonyl-
ureas may, on the one hand, increase intracellular Ca21
loading, and thereby accelerate cell death (78), or increase the
incidence of arrhythmias caused by delayed afterdepolariza-
tions; on the other hand, they may prevent arrhythmias caused
by reentry (33,86,88–90).
Of note, although the potential effects of sulfonylurea drugs
on triggered activity are theoretically interesting, the clinical
relevance of this action is questionable in the setting of acute
myocardial ischemia, where reentry is believed to be the major
cause of fatal, early (Harris phase I) arrhythmias (91). Indeed,
thus far only an antiarrhythmic action of sulfonylureas has
been demonstrated in humans during myocardial ischemia
(92,93). In some (90,94) but not all (95) studies, sulfonylurea
drugs have also been reported to alter the ST segment and T
wave configuration on the rest electrocardiogram (ECG) dur-
ing acute myocardial ischemia. Specifically, the magnitude of
ST segment elevation and early peaking of the T wave during
experimentally induced myocardial infarction was significantly
reduced after pretreatment with glyburide (94). Such a prop-
erty of sulfonylurea drugs acting on the ischemic myocardium
could therefore decrease the sensitivity of the ECG as a
diagnostic tool in some patients with acute myocardial infarc-
tion.
Structure of KATP Channels: Implications for
Future Use of Sulfonylurea Drug Therapy?
The structural components of the KATP channel have only
recently been determined (20,25). The KATP channel complex
exists as a heteromultimer formed by assembly of two subunits:
an inwardly rectifying potassium channel (Kir6.2) and the SUR
(Fig. 3) (20,25,28,96–99). Kir6.2 is the presumed pore-forming
subunit responsible for K1 conductance, which when intact can
function only when coexpressed with the SUR subunit, the
latter serving a regulatory role and as the binding site for
sulfonylurea drugs (20,25,96). In the absence of SUR, Kir6.2
can conduct K1 only after deletion of its carboxy terminal
domain (100). One potentially important discovery, made
recently, is the tissue-specific heterogeneity of the SUR sub-
unit, which exists in several isoforms named SUR1, SUR2A
and SUR2B (20,25,28,96,97,101). The SUR1 isoform, when
heterologously coexpressed and coassembled with Kir6.2, re-
constitutes the pancreatic KATP channel phenotype
(20,25,96,98,99). Cardiac (SUR2A) and vascular (SUR2B)
sulfonylurea receptors are structurally different from their
pancreatic analog (97,101,102). One area of intense research is
to understand more fully the structural and functional differ-
ences between pancreatic and cardiac isoforms of KATP chan-
nels (96,97,103), to determine whether sufficient differences
exist to allow development of sulfonylurea compounds that
interact exclusively with the pancreatic KATP channel, leaving
the cardiac channel unaffected. “Selective” targeting of pan-
creatic KATP channels by “beta-cell–selective sulfonylureas”
could represent a new strategy in the pharmacologic manage-
ment of diabetic patients with ischemic heart disease. How-
ever, it should be pointed out that the SUR subunit has also
been reported to be capable of functionally interacting with
inwardly rectifying K1 channels other than Kir6.2, suggesting
that additional ion channels may also be targeted by sulfonyl-
Figure 3. KATP channels in the pancreas and heart. Metabolism-
sensitive KATP channels are distributed in high density in pancreatic
beta-cells and cardiomyocytes. Molecular cloning and heterologous
expression studies suggest that the channel is a heteromultimer
composed of two subunits. The SUR (red) coassembles in the plasma
membrane with Kir6.2 (blue) to form a functional KATP channel
complex. Although the overall structure of the channel is thought to be
similar regardless of the tissue, structural differences do exist. In the
heart, the SUR subunit has been identified as the SUR2A isoform,
with 68% identity with the SUR1 isoform present in the pancreas.
Sulfonylureas (yellow, SUR) and ATP inhibit KATP channel activity
apparently by binding to the SUR protein, although ATP may also
inhibit channel activity through interaction with Kir6.2. The Kir6.2
subunit is believed common to both the pancreatic and cardiac KATP
channel, and responsible for K1 flux.
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urea drugs (104). The functional importance of such interac-
tions in intact cardiomyocytes is not yet known.
Conclusions
It is apparent that sulfonylurea drugs have important
actions within the cardiovascular system that go beyond their
ability to induce release of insulin. In diabetic patients with
myocardial ischemia, sulfonylurea drugs may be harmful by
preventing endogenous cardioprotective mechanisms to act,
leading to enhanced cell death and arrhythmias caused by
delayed afterdepolarizations. In contrast, sulfonylurea drugs
may also prevent reentrant arrhythmias, such as ventricular
fibrillation, during ischemia. Until newer, more tissue-selective
sulfonylurea drugs become available, physicians caring for
patients with non–insulin-dependent diabetes mellitus and
ischemic cardiac disease should consider the complex effects of
sulfonylurea drugs acting within the ischemic myocardium.
At this time, many unresolved questions remain regarding
the basic properties of the KATP channel, its role under
pathophysiologic conditions (is it a “bad,” or a “good” chan-
nel?) and the cardiovascular consequences of KATP channel
inhibition by sulfonylurea drugs. With increasing understand-
ing of the molecular properties of the KATP channel (20) and
the consequences of disruption of KATP channel function
(105), at least some of these questions may be answered. At the
clinical level, sufficient data on the effect of sulfonylureas on
clinical outcomes, on which to base recommendations for the
use of these drugs in diabetic patients, are still lacking
(13,106,107).
We thank Robert L. Frye, MD (Mayo Clinic) for the impetus he provided to this
work.
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